(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 July 2002 (04.07.2002)

PCT

(10) International Publication Number
WO 02/051809 A1

(51) International Patent Classification[7]: C07D 211/34, 401/06, 405/06, 413/06, 417/06, A61K 31/41, 31/42, 31/425, 31/445, 31/47, 31/495, 31/505, A61P 3/04, 3/10

(21) International Application Number: PCT/US01/49301

(22) International Filing Date:
17 December 2001 (17.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/257,873 22 December 2000 (22.12.2000) US

(71) Applicant: SCHERING CORPORATION [US/US]; Patent Department - K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).


(72) Inventors: MCKITTRICK, Brian, A.; Millbrook Road, New Vernon, NJ 07976 (US). SU, Jing; 1398 Graymill Drive, Scotch Plains, NJ 07076 (US). CLADER, John, W.; 428 North Union Avenue, Cranford, NJ 07016 (US). LI, Shengjian; 3 Hudnut Lane, Belle Mead, NJ 08502 (US). GUO, Guihua; 44 Dogwood Drive, Plainsboro, NJ 08536 (US).

(74) Agent: MAGATTI, Anita, W.; Schering-Plough Corporation, Patent Department -K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM.

*[Continued on next page]*


(54) Title: PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY



( I )



( II )



( III )

(57) Abstract: Disclosed are compounds represented by structural formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein W is $R^1$-$CR^3R^{12}NR^4C(O)$- or $R^{11}C(O)NR^4$-; the dotted line is an optional double bond; X is $CHR^8$-, -C(O)-, or -C(=NOR$^9$)-; Y is (II); $R^1$ is optionally substituted cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkyl-alkyl; $R^2$ is optionally substituted aryl or heteroaryl; $R^3$ is alkyl, aryl or heteroaryl; $R^4$ and $R^{12}$ are H or alkyl; $R^8$ is H, alkyl or alkoxyalkyl; $R^9$ is H, alkyl or arylalkyl; $R^{10}$ is H, alkyl or aryl; $R^{11}$ is (III), or, when $R^2$ is $R^6$-heteroaryl or $R^{10}$ is not H, $R^{11}$ can also be $R^5$-phenylalkyl; n is 1-3 and m is 1-5; and $R^{14}$ is 1-3 substituents selected from H, alkyl, halogen, -OH, alkoxy and $CF_3$; and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of eating disorders and diabetes.

WO 02/051809 A1

**(84) Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

**Published:**

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*